scholarly journals Changes in hemodynamics and plasma vasoactive endocrinological factors with long-term administration of recombinant human erythropoietin in anemic patients undergoing chronic hemodialysis.

1993 ◽  
Vol 26 (1) ◽  
pp. 49-55
Author(s):  
Osamu Iimura ◽  
Nobuyuki Ura ◽  
Kzuaki Shimamoto ◽  
Shuji Yonekura ◽  
Yasuo Kudoh ◽  
...  
Keyword(s):  
Recombinant Human Erythropoietin ◽  
Chronic Hemodialysis ◽  
Human Erythropoietin ◽  
Term Administration

Long-Term Effects of Recombinant Human Erythropoietin on Macro-and Microcirculation in Chronic Hemodialysis Patients

1993 ◽  
Vol 11 (4) ◽  
pp. 237-247 ◽  
Author(s):  
J.J.J.M. Wirtz ◽  
K.M.L. Leunissen ◽  
W. van Kuijk ◽  
E.C. Cheriex ◽  
D.W. Slaaf ◽  
...  
Keyword(s):  
Recombinant Human Erythropoietin ◽  
Hemodialysis Patients ◽  
Chronic Hemodialysis ◽  
Long Term Effects ◽  
Human Erythropoietin

Long-Term Echocardiographic Examinations in Chronic Hemodialysis Patients Substituted with Recombinant Human Erythropoietin

1990 ◽  
Vol 8 (5) ◽  
pp. 272-278 ◽  
Author(s):  
Iris Löw-Friedrich ◽  
Peter Grützmacher ◽  
Winfried März ◽  
Maria Bergmann ◽  
Wilhelm Schoeppe
Keyword(s):  
Recombinant Human Erythropoietin ◽  
Hemodialysis Patients ◽  
Chronic Hemodialysis ◽  
Human Erythropoietin

Treatment of the Anemia of Hemodialysis Patients with Recombinant Human Erythropoietin

1988 ◽  
Vol 11 (4) ◽  
pp. 249-254 ◽  
Author(s):  
R.M. Schaefer ◽  
B. Kuerner ◽  
M. Zech ◽  
G. Denninger ◽  
C. Borneff ◽  
...  
Keyword(s):  
Recombinant Human Erythropoietin ◽  
Antibody Formation ◽  
Hemodialysis Patients ◽  
Dialysis Session ◽  
Allergic Reactions ◽  
Human Erythropoietin ◽  
Major Organ ◽  
Baseline Values ◽  
Organ Dysfunctions

Fifteen long-term hemodialysis patients suffering from stable anemia received recombinant human erytheropoietin (r-huEPO). The hormone was given intravenously at the end of each dialysis session starting with a dose of 24 IU/kg. This dose was doubled when hemoglobin levels did not rise within 2 weeks. The number of reticulocytes started to increase after 14 days of treatment. The hematocrit rose from baseline values of 23.7 ± 1.2% to 32.4 ± 1.3% after 24 weeks of treatment. In parallel, hemoglobin values increased from 7.3 ± 0.3 g/100 ml to 10.1 ± 0.4 g/100 ml. As for side effects, 3 patients developed hypertension and 2 patients suffered from occlusions of their arterio-venous fistulas. There was no evidence of major organ dysfunctions, toxic effects, allergic reactions, or antibody formation. These data show that rHuEPO is able to correct the anemia of patients undergoing hemodialysis treatment.

Sign in / Sign up

Export Citation Format

Share Document